Category: NxStage Medical Inc.
NxStage Medical shares are up today on news that the Centers for Medicare & Medicaid Services raised the training payment for home hemodialysis and scrapped its proposal to cut the reimbursement rate for dialysis.
NxStage Medical (NSDQ:NXTM) shares are on the rise this morning after the Centers for Medicare & Medicaid Services announced Friday that it will boost the training rate for home hemodialysis.
NXTM shares were trading at $9.98 apiece as of about 10 a.m. today, up 3.5%.
NxStage touts its System One S, Nx2me Connected Health and Dosing Calculator at the American Society of Nephrology's Annual Kidney Week 2013.
NxStage Medical (NSDQ:NXTM) debuted 3 new products this week during the American Society of Nephrology's Annual Kidney Week 2013.
The Lawrence, Mass-based medical device company trotted out its System One S, the next generation of NxStage's System One. It features higher dialysate flow rates, allowing for a wider range of flexible therapy options.
Company officials at NxStage Medical discuss the company's Q3 2013 earnings call. The company reported losses of $5 million, or 8¢ per share, on sales of $66.9 million for the 3 months ended Sept. 30, for a 9.4% boost to sales and a near doubling of losses.
Shares of NxStage Medical lose upwards of 17% on Wall Street today after the company releases Q3 numbers with lackluster home hemodialysis growth and lowered expectations for the rest of the year.
NxStage Medical says it opened its 1st dialysis center near St. Louis.
NxStage Medical (NSDQ:NXTM) said its NxStage Kidney Care division opened its 1st dialysis center outside of St. Louis after winning Medicare certification from the Missouri Board of Health.
NxStage Medical urges the Centers for Medicare & Medicaid Services to boost reimbursement rates for home hemodialysis treatments.
Home hemodialysis system maker NxStage Medical (NSDQ:NXTM) urged the Centers for Medicare & Medicaid Services to increase coverage for home hemodialysis training for patients with end-stage renal disease.
NxStage Medical shares dive nearly 4% on Wall Street today, despite higher revenues and narrowed losses in the 2nd quarter.
NxStage Medical (NSDQ:NXTM) beat the Street's earnings-per-share estimate by 1 penny and reported an 11% bump in sales, but it wasn't enough to stop shares from sliding 4% this morning.